ALEC
NASDAQAlector Inc.
Website
News25/Ratings12
News · 26 weeks38-80%
2025-10-262026-04-19
Mix2190d
- Insider9(43%)
- Other5(24%)
- SEC Filings5(24%)
- Analyst2(10%)
Latest news
25 items- INSIDERSEC Form 4 filed by Wong-Sarad Grace4 - Alector, Inc. (0001653087) (Issuer)
- ANALYSTAlector upgraded by Cantor FitzgeraldCantor Fitzgerald upgraded Alector from Neutral to Overweight
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Alector Inc.SCHEDULE 13G/A - Alector, Inc. (0001653087) (Subject)
- INSIDERChief Executive Officer Rosenthal Arnon was granted 116,246 shares, increasing direct ownership by 5% to 2,454,422 units (SEC Form 4)4 - Alector, Inc. (0001653087) (Issuer)
- INSIDERCFO & Chief Business Officer Berkley Neil Lindsay was granted 54,600 shares, increasing direct ownership by 16% to 399,260 units (SEC Form 4)4 - Alector, Inc. (0001653087) (Issuer)
- INSIDERPrincipal Accounting Officer Wong-Sarad Grace sold $2,650 worth of shares (1,000 units at $2.65), decreasing direct ownership by 0.93% to 106,465 units (SEC Form 4)4 - Alector, Inc. (0001653087) (Issuer)
- SECSEC Form S-3 filed by Alector Inc.S-3 - Alector, Inc. (0001653087) (Filer)
- ANALYSTAlector upgraded by BTIG Research with a new price targetBTIG Research upgraded Alector from Neutral to Buy and set a new price target of $6.00
- INSIDERPrincipal Accounting Officer Wong-Sarad Grace sold $7,012 worth of shares (3,367 units at $2.08), decreasing direct ownership by 3% to 107,465 units (SEC Form 4)4 - Alector, Inc. (0001653087) (Issuer)
- INSIDERPrincipal Accounting Officer Wong-Sarad Grace sold $17,138 worth of shares (8,071 units at $2.12), decreasing direct ownership by 7% to 110,832 units (SEC Form 4)4 - Alector, Inc. (0001653087) (Issuer)
- INSIDERChief Executive Officer Rosenthal Arnon sold $173,822 worth of shares (81,864 units at $2.12), decreasing direct ownership by 3% to 2,338,176 units (SEC Form 4)4 - Alector, Inc. (0001653087) (Issuer)
- INSIDERCFO & Chief Business Officer Berkley Neil Lindsay sold $62,954 worth of shares (29,649 units at $2.12), decreasing direct ownership by 8% to 344,660 units (SEC Form 4)4 - Alector, Inc. (0001653087) (Issuer)
- SECSEC Form 144 filed by Alector Inc.144 - Alector, Inc. (0001653087) (Subject)
- INSIDERPrincipal Accounting Officer Wong-Sarad Grace sold $10,198 worth of shares (4,079 units at $2.50), decreasing direct ownership by 3% to 118,903 units (SEC Form 4)4 - Alector, Inc. (0001653087) (Issuer)
- SECSEC Form S-8 filed by Alector Inc.S-8 - Alector, Inc. (0001653087) (Filer)
- SECSEC Form 10-K filed by Alector Inc.10-K - Alector, Inc. (0001653087) (Filer)
- SECAlector Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Alector, Inc. (0001653087) (Filer)
- PRAlector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateAdvancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid antibody for Alzheimer's Disease), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's Disease) and AL064 (ABC-enabled Tau siRNA for Alzheimer's Disease) Independent interim futility analysis of the PROGRESS-AD Phase 2 trial of nivisnebart (AL101) in early Alzheimer's disease expected in the first half of 2026 $256.0 million in cash, cash equivalents and investments provide runway at least through 2027 SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Alector, Inc.
- PRAlector to Participate in the TD Cowen 46th Annual Health Care ConferenceSOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a corporate presentation at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 3:10 pm ET. A live webcast of the corporate presentation will be available on the "Events & Presentations" page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 90 days following the event. About AlectorAlector is a clini
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Alector Inc.SCHEDULE 13G/A - Alector, Inc. (0001653087) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Alector Inc.SCHEDULE 13G/A - Alector, Inc. (0001653087) (Subject)
- SECAlector Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Alector, Inc. (0001653087) (Filer)
- PRAlector Appoints Neil Berkley as Chief Financial Officer and Chief Business OfficerSOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Neil Berkley, who has served as Alector's Chief Business Officer (CBO) since March 2024, and CBO and Interim Chief Financial Officer (CFO) since June 2025, has been appointed CFO, effective December 10, 2025. Mr. Berkley will continue to serve as CBO. "Neil has demonstrated exceptional leadership, judgment, strategic insight, and an unwavering commitment to Alector's mission," said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. "His
- INSIDERPrincipal Accounting Officer Wong-Sarad Grace sold $5,751 worth of shares (4,753 units at $1.21), decreasing direct ownership by 4% to 122,982 units (SEC Form 4)4 - Alector, Inc. (0001653087) (Issuer)
- INSIDERSEC Form 4 filed by Alector Inc.4 - Alector, Inc. (0001653087) (Issuer)